We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Immune-Related Pneumonitis Was Decreased by Addition of Chemotherapy with PD-1/L1 Inhibitors: Systematic Review and Network Meta-Analysis of Randomized Controlled Trials (RCTs).
- Authors
Long, Yi-Xiu; Sun, Yue; Liu, Rui-Zhi; Zhang, Ming-Yi; Zhao, Jing; Wang, Yu-Qing; Zhou, Yu-Wen; Cheng, Ke; Chen, Ye; Zhu, Cai-Rong; Liu, Ji-Yan
- Abstract
Purpose: Immune-related pneumonitis (IRP) has attracted extensive attention, owing to its increased mortality rate. Conventional chemotherapy (C) has been considered as an immunosuppressive agent and may thus reduce IRP's risk when used in combination with PD-1/L1 inhibitors. This study aimed to assess the risk of IRP with PD-1/L1 inhibitors plus chemotherapy (I+C) versus PD-1/L1 inhibitors alone (I) in solid cancer treatment. Method: Multiple databases were searched for RCTs before January 2021. This NMA was performed among I+C, I, and C to investigate IRP's risk. Subgroup analysis was carried out on the basis of different PD-1/L1 inhibitors and cancer types. Results: Thirty-one RCTs (19,624 patients) were included. The I+C group exhibited a lower risk of IRP in any grade (RR, 0.60; 95% CI, 0.38–0.95) and in grade 3–5 (RR, 0.44; 95% CI, 0.21–0.92) as opposed to the I group. The risk of any grade IRP with PD-1 plus chemotherapy was lower than that with PD-1 monotherapy (RR, 0.50; 95% CI, 0.28–0.89), although grade 3–5 IRP was similar. There was no statistically meaningful difference in the risk of any grade IRP between PD-L1 plus chemotherapy and PD-L1 inhibitors monotherapy (RR, 0.95; 95% CI, 0.43–2.09) or grade 3–5 IRP (RR, 0.71;95% CI, 0.24–2.07). In addition, compared with the I group, the I+C group was correlated with a decreased risk in IRP regardless of cancer type, while a substantial difference was only observed in NSCLC patients for grade 3–5 IRP (RR, 0.39; 95% CI, 0.15–0.98). Conclusion: In comparison to PD-1/L1 inhibitor treatment alone, combining chemotherapy with PD-1/L1 inhibitors might reduce the risk of IRP in the general population. Furthermore, PD-1 inhibitors in combination with chemotherapy were correlated with a decreased risk of IRP compared to PD-1 inhibitor treatment alone. In contrast to the I group, the I+C group exhibited a lower risk of IRP, especially for NSCLC patients.
- Subjects
RANDOMIZED controlled trials; PNEUMONIA; CANCER chemotherapy; MTOR inhibitors; COMBINATION drug therapy; PROGRAMMED cell death 1 receptors; PNEUMONIA prevention; THERAPEUTIC use of antineoplastic agents; ONLINE information services; META-analysis; CONFIDENCE intervals; MEDICAL information storage &; retrieval systems; MEDICAL databases; INFORMATION storage &; retrieval systems; SYSTEMATIC reviews; TREATMENT effectiveness; IMMUNOLOGIC diseases; MEMBRANE proteins; IMMUNOSUPPRESSIVE agents; ODDS ratio; MEDLINE; CHEMICAL inhibitors
- Publication
Current Oncology, 2022, Vol 29, Issue 1, p267
- ISSN
1198-0052
- Publication type
Article
- DOI
10.3390/curroncol29010025